Life sciences company Monod Bio announced on Monday the launch of NovoLISA, a rapid biosensor assay platform targeting the research use only (RUO) and in vitro diagnostics (IVD) markets.

NovoLISA delivers results in 15 minutes, significantly faster than traditional methods like ELISA assays. The platform's name stands for "de Novo protein-Linked Instantaneous Solution-based Assay" and debuts with a C-Reactive Protein (CRP) assay. NovoLISA integrates two proprietary technologies: the LuxSit Pro luciferase reporter and de novo binding proteins, enabling fast and simple assays. Key features include a one-step, no-wash protocol, no sample preparation and compatibility with standard luminescence plate readers.

The CRP NovoLISA kit includes Split LuxSit CRP Biosensor proteins, LuxSit Substrate, assay buffer and CRP analyte. Upon sample addition, luminescence increases in a dose-dependent manner with low background, delivering rapid results.